My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 471

    1.

    Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.

    Rommers MK, Van der Lely N, Egberts TC, van den Bemt PM.

    Crit Care. 2006;10(3):R93. Epub 2006 Jun 21.PMID: 16790078 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?

    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.

    Crit Care Med. 2003 May;31(5):1405-9.PMID: 12771610 [PubMed - indexed for MEDLINE]Related articles

    3.

    Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.

    Stöbe J, Siegemund A, Achenbach H, Preiss C, Preiss R.

    Int J Clin Pharmacol Ther. 2006 Oct;44(10):455-65.PMID: 17063975 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.

    Wilson SJ, Wilbur K, Burton E, Anderson DR.

    Haemostasis. 2001 Jan-Feb;31(1):42-8.PMID: 11408748 [PubMed - indexed for MEDLINE]Related articles

    5.

    Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.

    Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ.

    J Crit Care. 2005 Dec;20(4):357-63.PMID: 16310608 [PubMed - indexed for MEDLINE]Related articles

    6.

    A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.

    Perry SL, O'Shea SI, Byrne S, Szczech LA, Ortel TL.

    Thromb Haemost. 2006 Dec;96(6):750-5.PMID: 17139369 [PubMed - indexed for MEDLINE]Related articles

    7.

    Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.

    Kovacs MJ, Levine MN, Keeney M, Mackinnon KM, Lee AY.

    Thromb Haemost. 2005 Jun;93(6):1185-8.PMID: 15968406 [PubMed - indexed for MEDLINE]Related articles

    8.

    Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.

    Oldgren J, Johnston N, Siegbahn A.

    Am Heart J. 2008 Mar;155(3):493.e1-8.PMID: 18294482 [PubMed - indexed for MEDLINE]Related articles

    9.

    Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.

    Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A.

    Thromb Haemost. 2001 Dec;86(6):1374-8.PMID: 11776302 [PubMed - indexed for MEDLINE]Related articles

    10.

    Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).

    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.

    Thromb Haemost. 1998 Jun;79(6):1162-5.PMID: 9657442 [PubMed - indexed for MEDLINE]Related articles

    11.

    Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.

    Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group.

    Arch Intern Med. 2008 Sep 8;168(16):1805-12.PMID: 18779469 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.

    Kani C, Markantonis SL, Nicolaou C, Maggina N.

    J Crit Care. 2006 Mar;21(1):79-84.PMID: 16616629 [PubMed - indexed for MEDLINE]Related articles

    13.

    Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.

    Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sié P.

    Thromb Haemost. 1998 Feb;79(2):338-41.PMID: 9493587 [PubMed - indexed for MEDLINE]Related articles

    14.

    A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.

    Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD.

    Crit Care Med. 1999 Oct;27(10):2224-8.PMID: 10548211 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

    Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ.

    Thromb Haemost. 1995 Apr;73(4):630-40.PMID: 7495071 [PubMed - indexed for MEDLINE]Related articles

    16.

    Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.

    Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek HJ Jr.

    Thromb Res. 2001 Feb 15;101(4):243-54.PMID: 11248285 [PubMed - indexed for MEDLINE]Related articles

    17.

    Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.

    de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF.

    Crit Care Med. 2000 Feb;28(2):421-5.PMID: 10708177 [PubMed - indexed for MEDLINE]Related articles

    18.

    Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy.

    Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK, Hekmatpanah J, Frim D.

    Surg Neurol. 2003 May;59(5):363-72; discussion 372-4.PMID: 12765806 [PubMed - indexed for MEDLINE]Related articles

    19.

    Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.

    Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K.

    Thromb Haemost. 1996 Aug;76(2):195-9.PMID: 8865530 [PubMed - indexed for MEDLINE]Related articles

    20.

    Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level.

    Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di Castillo H, Siguret V, Bergmann JF, Pautas E.

    Drugs Aging. 2007;24(1):63-71.PMID: 17233548 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity